Key result
Three-protein panel plus liver enzymes improves steatotic liver disease prediction to AUC ~0.83.
Why the study?
Do circulating proteomic signatures predict cardiometabolic risk and steatotic liver disease in children and adolescents with obesity?
Cross-Sectional (n=4,024)
Do circulating proteomic signatures predict cardiometabolic risk and steatotic liver disease in children and adolescents with obesity?
Answers are grounded in this paper and cite their sources.
A three-protein panel improves the prediction of steatotic liver disease in youth with obesity, and these inflammatory markers decrease with non-pharmacological obesity interventions.
Pediatric obesity is linked to multi-organ inflammation and an increased risk of cardiometabolic and steatotic liver disease. To identify circulating biomarkers of cardiometabolic risk, we performed proximity extension assay proteomics, to quantify 149 inflammation- and cardiovascular-related proteins in a cross-sectional study of 4024 children and adolescents (2377 with obesity and 1647 with normal weight). We identified protein signatures linked to obesity, dyslipidemia, insulin resistance, hyperglycemia, hypertension, and related cardiometabolic phenotypes. Using machine learning, a three-protein panel (CDCP1, FGF21, HAOX1) combined with liver enzymes improved prediction of steatotic liver disease versus liver enzymes alone (receiver operating characteristic-area under the curve (ROC-AUC) = 0.83 vs. 0.77; DeLong's test, P < 0.05). During a 1-year non-pharmacological obesity intervention (n = 184), reductions in adiposity were associated with decreased inflammatory cytokines (including CDCP1, FGF21), which correlated with improvements in cardiometabolic risk profiles. Here we show that circulating proteomic signatures may mediate obesity-related cardiometabolic risk in youth.
No takes yet. Share an insight, caveat, or question.
Stinson et al. (2026) conducted a cross-sectional in Obesity (n=4,024). Three-protein panel (CDCP1, FGF21, HAOX1) combined with liver enzymes vs. Liver enzymes alone was evaluated on Prediction of steatotic liver disease (ROC-AUC) (p=<0.05). A three-protein panel (CDCP1, FGF21, HAOX1) combined with liver enzymes improved the prediction of steatotic liver disease compared to liver enzymes alone.
Synapse has enriched 10 related papers. Consider them for comparative context: